Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Broken support ⢠Lower highs ⢠Weak momentum Support Level: $42.69 Resistance Level: $46-$49 TEM is in a clear downtrend over the last month, with support broken near $48.4â$49.0 and downside risk elevated despite a possible bounce from the $42.69 low.
Sentiment & News
Key News Insights: ⢠Personalis Deal ⢠OneOme Launch ⢠Diagnostics Growth Tempus AI is rapidly expanding its precision medicine platform through the Personalis acquisition and OneOme launch, but the all-stock deal has triggered dilution concerns despite strong growth and analyst optimism.
AI Summary
TEM's investment case has shifted from pure precision-medicine growth to an execution-and-capital-allocation story: revenue and gross profit are accelerating, but upside now depends on Tempus converting that growth into durable margins while avoiding dilution, integration missteps from Personalis, and continued financing pressure.
Description
Tempus AI, Inc. is a healthcare technology company that performs molecular diagnostics, including next-generation sequencing, PCR profiling, genotyping and anatomic pathology for healthcare providers, pharmaceutical and biotechnology firms, and researchers. It also licenses a de-identified, linked clinicalâmolecularâimaging dataset and offers analytics, cloud compute tools, clinical trial matching, algorithmic oncology tests and software for test ordering and research workflows. The company entered strategic collaborations with AstraZeneca and Pathos AI, was incorporated in 2015, changed its name from Tempus Labs in January 2023, and is headquartered in Chicago, Illinois.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 9 | Dec 16 | TEM | Tempus AI, Inc. | Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential. | Closed | -10.2% |